Smoking Cessation Algorithm for HIV/AIDS Patients
Trial Summary
What is the purpose of this trial?
To determine the efficacy of an algorithm designed to recommend smoking cessation-related pharmacotherapy options to the primary care providers of smokers living with HIV/AIDS.
Do I have to stop taking my current medications to join the trial?
The trial protocol does not specify whether you need to stop taking your current medications.
What data supports the idea that Smoking Cessation Algorithm for HIV/AIDS Patients is an effective treatment?
The available research shows that smoking cessation programs can be effective for HIV patients, but the success rate can vary. For example, a study in Newark, New Jersey, found that 16% of HIV patients who participated in a smoking cessation program were able to quit smoking after six months. This suggests that while the treatment can help some people quit smoking, it may not work for everyone. The study also highlighted that people who were ready to change their smoking habits were more likely to succeed. Compared to other treatments, like multiple counseling sessions in hospitals, which have shown to increase quit rates, the Smoking Cessation Algorithm for HIV/AIDS Patients may need more support to improve its effectiveness.12345
What safety data exists for the Smoking Cessation Algorithm for HIV/AIDS patients?
The available research does not provide specific safety data for the Smoking Cessation Algorithm itself. However, a pilot study showed that the algorithm successfully engaged participants in using cessation medications and changing smoking behaviors, with no specific safety concerns reported. Additionally, a separate study on the safety of varenicline, a smoking cessation medication, in people living with HIV, was conducted, but the results are not detailed in the provided abstracts.36789
Is the treatment 'Algorithm Treatment, Quitline only' a promising treatment for helping HIV/AIDS patients quit smoking?
Yes, the treatment is promising because it successfully engaged participants to use smoking cessation medications and reduced their smoking habits. Participants in the study decreased their cigarette use from 14.4 to 7.1 cigarettes per day over three months, and 45% made a 24-hour quit attempt. This shows that the treatment can help HIV/AIDS patients reduce smoking and attempt to quit.3561011
Research Team
Eligibility Criteria
This trial is for adults over 18 who smoke more than 5 cigarettes daily, live in a place where smoking is allowed, are part of the CNICS cohort, and receive HIV care at specific clinics without plans to change. It's not for those with cognitive impairments, non-English speakers, people already in cessation treatment or unstable individuals.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Algorithm Treatment (Behavioural Intervention)
- Quitline only (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Alabama at Birmingham
Lead Sponsor
Kierstin Kennedy
University of Alabama at Birmingham
Chief Medical Officer since 2022
MD
S. Dawn Bulgarella
University of Alabama at Birmingham
Chief Executive Officer since 2023
BSc in Commerce and Business Administration from the University of Alabama, MS in Health Administration from the University of Alabama at Birmingham
National Institute on Drug Abuse (NIDA)
Collaborator
Dr. Nora Volkow
National Institute on Drug Abuse (NIDA)
Chief Executive Officer since 2003
MD from National Autonomous University of Mexico
Dr. Nora Volkow
National Institute on Drug Abuse (NIDA)
Chief Medical Officer since 2003
MD from National Autonomous University of Mexico
University of Washington
Collaborator
Dr. Timothy H. Dellit
University of Washington
Chief Executive Officer since 2023
MD from University of Washington
Dr. Anneliese Schleyer
University of Washington
Chief Medical Officer since 2023
MD, MHA
Harvard University
Collaborator
Dr. Christopher Anzalone
Harvard University
Chief Executive Officer since 2007
PhD in Biology from UCLA
Dr. Perry
Harvard University
Chief Medical Officer since 2011
MD from Albert Einstein College of Medicine, MPH from Harvard University